Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
TRQyAKDeuknhhX8V
Écouter
